GDRX
GoodRx Holdings, Inc. NASDAQ Listed Sep 23, 2020$2.57
After hrs
$2.57
-0.10%
Mkt Cap $880.7M
52w Low $1.77
19.8% of range
52w High $5.81
50d MA $2.21
200d MA $3.13
P/E (TTM)
29.9x
EV/EBITDA
4.1x
P/B
1.5x
Debt/Equity
0.1x
ROE
4.9%
P/FCF
5.9x
RSI (14)
—
ATR (14)
—
Beta
1.47
50d MA
$2.21
200d MA
$3.13
Avg Volume
2.8M
About
GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money …
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | AMC | 0.09 | 0.09 | +0.0% | 2.45 | -18.8% | -18.8% | -23.7% | -11.4% | -15.5% | -11.0% | — |
| Nov 4, 2025 | AMC | 0.09 | 0.08 | -11.1% | 3.26 | +3.1% | +2.1% | -3.1% | -4.6% | -6.1% | -7.1% | — |
| Aug 6, 2025 | AMC | 0.10 | 0.09 | -10.0% | 4.34 | -7.8% | -20.0% | -20.0% | -19.8% | -19.4% | -18.0% | — |
| May 7, 2025 | AMC | 0.09 | 0.09 | +0.0% | 3.79 | +6.3% | +11.9% | +14.0% | +14.8% | +13.5% | +12.7% | — |
| Feb 27, 2025 | AMC | 0.10 | 0.09 | -10.0% | 4.98 | -2.0% | +0.0% | -2.6% | -6.2% | -0.8% | -6.8% | — |
| Nov 7, 2024 | AMC | 0.09 | 0.08 | -11.1% | 5.04 | +1.6% | -3.0% | -3.0% | -6.7% | -7.5% | -9.5% | — |
| Aug 8, 2024 | AMC | 0.09 | 0.08 | -11.1% | 7.01 | +5.3% | +2.9% | -3.3% | -2.0% | -2.3% | -1.3% | — |
| May 9, 2024 | AMC | 0.09 | 0.08 | -11.1% | 6.93 | -1.0% | -4.8% | -3.3% | -4.0% | +4.9% | +16.3% | — |
| Feb 29, 2024 | AMC | 0.08 | 0.08 | +0.0% | 7.79 | +6.8% | +7.2% | +3.7% | -2.3% | -2.8% | -3.2% | — |
| Nov 9, 2023 | AMC | 0.06 | 0.06 | +0.0% | 4.44 | +0.0% | +7.9% | +6.1% | +12.4% | +18.9% | +17.1% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 4 | Wells Fargo | Maintains | Overweight → Overweight | — | $2.07 | $2.08 | +0.5% | +5.3% | +10.6% | +10.1% | +13.5% | +15.9% |
| Mar 3 | Citigroup | Maintains | Buy → Buy | — | $2.17 | $2.09 | -3.7% | -4.6% | +0.5% | +5.5% | +5.1% | +8.3% |
| Mar 2 | Goldman Sachs | Maintains | Neutral → Neutral | — | $1.87 | $1.80 | -3.7% | +16.0% | +10.7% | +16.6% | +22.5% | +21.9% |
| Feb 27 | JP Morgan | Downgrade | Overweight → Neutral | — | $1.99 | $1.99 | +0.0% | -6.0% | +9.0% | +4.0% | +9.5% | +15.1% |
| Feb 27 | Mizuho | Maintains | Neutral → Neutral | — | $1.99 | $1.99 | +0.0% | -6.0% | +9.0% | +4.0% | +9.5% | +15.1% |
| Jan 22 | Jefferies | Downgrade | Buy → Hold | — | $2.58 | $2.50 | -3.1% | -0.4% | -0.8% | -2.3% | -9.7% | -9.3% |
| Jan 9 | Citigroup | Maintains | Buy → Buy | — | $2.79 | $2.78 | -0.4% | +0.4% | +3.2% | +2.5% | -1.4% | -3.9% |
| Dec 18 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $2.78 | $2.76 | -0.7% | -1.4% | -0.4% | -2.5% | -1.1% | -0.4% |
| Nov 11 | JP Morgan | Maintains | Overweight → Overweight | — | $3.06 | $3.04 | -0.7% | -1.0% | +0.0% | +0.3% | -2.9% | -6.9% |
| Nov 10 | TD Cowen | Maintains | Buy → Buy | — | $3.11 | $3.13 | +0.6% | -1.6% | -2.6% | -1.6% | -1.3% | -4.5% |
Recent Filings
8-K · 5.02
!!! Very High
GoodRx Holdings, Inc. -- 8-K 5.02: Executive Change
GoodRx appointed Thomas Chan as Chief Accounting Officer, strengthening its financial leadership and accounting oversight capabilities.
Apr 24
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The departure of an executive at GoodRx signals potential uncertainty about strategic direction and could pressure the stock if the departing executive held critical operational or strategic responsibilities.
Apr 3
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
GoodRx's departure of an executive signals potential leadership instability and may indicate internal challenges, risking investor confidence and operational continuity during a critical period.
Mar 27
8-K · 4.01
!!! Very High
Unknown — 8-K 4.01: Auditor Change / Resignation
GoodRx's auditor resignation without dispute raises concerns about potential accounting issues or cost pressures, warranting closer examination of financial statements and governance before investing.
Mar 18
8-K · 5.02
!!! Very High
GoodRx Holdings, Inc. -- 8-K 5.02: Executive Change
GoodRx's executive departure increases investor uncertainty about leadership stability and strategic direction, potentially pressuring the stock until a replacement is announced and market confidence in continuity is restored.
Mar 6
8-K · 5.02
!!! Very High
GoodRx Holdings, Inc. -- 8-K 5.02: Executive Change
GoodRx Holdings' director Dipanjan Deb resigned, which may signal internal shifts in leadership but doesn't materially impact the company's operations or investor outlook.
Feb 27
8-K
GoodRx Holdings, Inc. -- 8-K Filing
GoodRx delivered 2025 results in line with guidance while Pharma Direct revenue exceeded expectations with over 40% year-over-year growth, demonstrating strength in its higher-margin business segment.
Feb 25
Data updated apr 25, 2026 10:58am
· Source: massive.com